Pharmacyclics Price Target Raised to $180.00 at William Blair (PCYC)
Analysts at William Blair upped their price objective on shares of Pharmacyclics (NASDAQ:PCYC) from $150.00 to $180.00 in a research report issued to clients and investors on Tuesday. The firm currently has an “outperform” rating on the stock. William Blair’s price objective suggests a potential upside of 51.18% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Pharmacyclics in a research note on Friday. They now have a $180.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Pharmacyclics in a research note on Friday. They now have a $152.00 price target on the stock, up previously from $150.00. Finally, analysts at RBC Capital raised their price target on shares of Pharmacyclics from $95.00 to $100.00 in a research note on Friday. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $155.33.
Pharmacyclics (NASDAQ:PCYC) opened at 118.10 on Tuesday. Pharmacyclics has a 52 week low of $82.51 and a 52 week high of $154.89. The stock’s 50-day moving average is $98.22 and its 200-day moving average is $108.8. The company has a market cap of $8.874 billion and a P/E ratio of 106.40.
Pharmacyclics (NASDAQ:PCYC) last posted its quarterly earnings results on Thursday, July 31st. The company reported ($0.26) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.23) by $0.03. The company had revenue of $113.00 million for the quarter, compared to the consensus estimate of $95.88 million. During the same quarter last year, the company posted $0.25 earnings per share. Pharmacyclics’s revenue was up 106.6% compared to the same quarter last year. Analysts expect that Pharmacyclics will post $0.36 EPS for the current fiscal year.
Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.
Receive News & Ratings for Pharmacyclics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmacyclics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.